Pentoxifylline

CHEMBL628 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
278.3 g/mol
LogP
0.3
Phase
4

This medication improves blood flow by making red blood cells more flexible, used for intermittent claudication.

Molecular Weight

278.3100 g/mol

LogP

0.30

TPSA

75.50 Ų

Lipinski RO5

Pass

Therapeutic Areas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O

InChI

InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3

Molecular Formula

C13H18N4O3

HBD / HBA

- / 4

Rotatable Bonds

5

Heavy Atoms

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This medication improves blood flow by making red blood cells more flexible, used for intermittent claudication.

Yes, Pentoxifylline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL628. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4740. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.